Regencell Bioscience Holdings Ltd Asset Resilience Ratio
Regencell Bioscience Holdings Ltd asset resilience ratio. Regencell Bioscience Holdings Ltd (RGC) has an Asset Resilience Ratio of 43.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Regencell Bioscience Holdings Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Regencell Bioscience Holdings Ltd (2011–2025)
Asset resilience ratio of Regencell Bioscience Holdings Ltd from 2011 to 2025. This chart shows how Regencell Bioscience Holdings Ltd's Asset Resilience Ratio has changed over time. Read debt load of Regencell Bioscience Holdings Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Regencell Bioscience Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Regencell Bioscience Holdings Ltd (RGC) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.48 Million | 43.05% |
| Total Liquid Assets | $2.48 Million | 43.05% |
Asset Resilience Insights
- Very High Liquidity: Regencell Bioscience Holdings Ltd maintains exceptional liquid asset reserves at 43.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Regencell Bioscience Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Regencell Bioscience Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Regencell Bioscience Holdings Ltd Asset Resilience Ratio by Year (2011–2025)
Regencell Bioscience Holdings Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Regencell Bioscience Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 43.05% | $2.48 Million | $5.76 Million | -16.20pp |
| 2024-06-30 | 59.25% | $5.00 Million | $8.44 Million | -19.97pp |
| 2023-06-30 | 79.23% | $10.00 Million | $12.62 Million | +23.73pp |
| 2022-06-30 | 55.50% | $10.00 Million | $18.02 Million | +55.35pp |
| 2015-06-30 | 0.15% | $3.80 Million | $2.54 Billion | -0.11pp |
| 2014-06-30 | 0.26% | $7.00 Million | $2.70 Billion | +0.02pp |
| 2011-06-30 | 0.24% | $6.00 Million | $2.49 Billion | -- |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more